Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Probenecid/sulopenem etzadroxil - Iterum Therapeutics

Next Previous
X
Search
Drug Profile

Probenecid/sulopenem etzadroxil - Iterum Therapeutics

Alternative Names: Oral sulopenem - Iterum Therapeutics; ORLYNVAH; PF 03709270/probenecid; PF-3709270//probenecid; Sulopenem etzadroxil/ probenecid - Iterum Therapeutics; Sulopenem/probenecid - Iterum Therapeutics

Latest Information Update: 30 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Iterum Therapeutics; Pfizer
  • Class Anti-infectives; Antibacterials; Antigouts; Aza compounds; Beta-lactams; Esters; Penems; Small molecules; Sulfonamides; Uricosurics
  • Mechanism of Action Cell wall inhibitors; Organic anion transport protein 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Urinary tract infections
  • Phase III Intra-abdominal infections
  • Discontinued Bacterial infections; Community-acquired pneumonia

Most Recent Events

  • 25 Oct 2024 Registered for Urinary tract infections in USA (PO)
  • 30 Jan 2024 Efficacy and safety data from a phase III REASSURE trial in Urinary tract infections released by Iterum Therapeutics
  • 31 Dec 2023 Iterum Therapeutics has patent protection related to composition of the bilayer tablet of oral sulopenem in USA, Japan, South Korea, Australia before December 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top